Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell